Palmitoyl Hexapeptide-12
Also known as: Biopeptide EL, Pal-VGVAPG, Palmitoyl Oligopeptide, Elastin-derived peptide
Key Facts: Palmitoyl Hexapeptide-12
- Category
- Skin & Hair
- FDA Status
- Not FDA Approved
- Clinical Status
- Cosmetic use - Widely available in skincare. Cosmetic ingredient, not an FDA-approved drug. No independent human efficacy trials published; the clinical claims come from small manufacturer studies.
- Banned in Sport (WADA)
- Not named on the WADA Prohibited List (2026). As a topical cosmetic ingredient it is not a known anti-doping issue, but injecting it as an unapproved drug would fall under WADA's S0 catch-all.
- Administration
- Topical (serums, creams)
- Typical Dose
- About 4% of the ingredient solution in a finished product
- Frequency
- Once or twice daily
- Duration
- Manufacturer study ran one month; ongoing use for any maintained effect
How does Palmitoyl Hexapeptide-12 work?
VGVAPG repeats many times in elastin, the protein that lets skin snap back. When elastin breaks down, fragments like this are released, and back in 1984 researchers showed VGVAPG attracts fibroblasts and monocytes in the lab, which is the basis for calling it a matrikine: a matrix fragment that tells repair cells to show up and get to work. The palmitoyl tail makes the peptide fat-friendly enough to cross the outer skin layer. A 2025 ex vivo study added a twist: on human skin samples the peptide reached the epidermis, used the skin's own calcium to form a gel, and helped dried-out, lipid-stripped skin hold water and stay less stiff. That reads more like a barrier and film effect than proof of new elastin being built.
What does the research show?
The best peer-reviewed work is a 2025 paper in ACS Applied Bio Materials (Ligorio and colleagues, with co-authors from Estee Lauder) that tracked the peptide in full-thickness human skin from a single donor. It showed penetration into the stratum corneum and epidermis, gel formation driven by calcium, reduced water loss and drying stress in delipidated skin (roughly comparable to 5 percent glycerol for drying stress), and stronger gels when mixed with collagen. Useful mechanistic data, but small samples and no living people. The appearance claims come from the manufacturer: a one-month, double-blind study in 10 women using 4 percent Biopeptide EL twice daily reported 33 percent better firmness and 20 percent better tone. That study is not in PubMed and is far too small to lean on. A separate 2023 trial of an elastin-like recombinant polypeptide built on the same VGVAPG repeat found improved elasticity after 28 days in 30 women, but that was a different molecule. Honest read: plausible biology, real skin penetration, no independent proof of visible results.
What doses have been studied?
Typical Dosingⓘ
Community experience
About 4% of the ingredient solution in a finished product
Not standardized; depends on the supplier solution
Once or twice daily
Cosmetic labels list the ingredient, not the actual peptide percentage, so you usually cannot tell how much is in a product. The 4 percent figure refers to the commercial ingredient blend used in the manufacturer study, not pure peptide.
Research Dosingⓘ
Scientific studies
Cosmetic formulation levels, not a dose recommendation
Doses from Studies
4% Biopeptide EL, twice daily
1% peptide solution applied ex vivo
Duration
Manufacturer study ran one month; ongoing use for any maintained effect
Administration
Topical (serums, creams)
When and how is Palmitoyl Hexapeptide-12 taken?
Best Time to Take
Morning and/or evening skincare routine
Once or twice daily on clean skin
Food Recommendation
With or without food
Why This Timing?
No evidence that time of day matters for a topical matrikine peptide. Consistent daily use is what the studies used.
What are the side effects of Palmitoyl Hexapeptide-12?
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well tolerated in cosmetic use
- ●Mild redness or irritation (uncommon)
- ●Possible breakouts from the cream base in acne-prone skin
- ●No meaningful systemic absorption expected from topical use
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11920943/
- https://incidecoder.com/ingredients/palmitoyl-hexapeptide-12
- https://www.specialchem.com/cosmetics/product/croda-biopeptide-el
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9827338/
Research This Peptide Further
Frequently Asked Questions
What does Palmitoyl Hexapeptide-12 do?
Palmitoyl hexapeptide-12 is the six-amino-acid sequence VGVAPG, a repeating piece of elastin, with a fatty acid tail attached so it can get into skin. It is sold under the trade name Biopeptide EL and pitched for firmness and elasticity, the bounce-back that fades with age. It is a cosmetic ingredient, not an FDA-approved drug, and nobody has published an independent clinical trial showing it visibly changes skin.
How does Palmitoyl Hexapeptide-12 work?
VGVAPG repeats many times in elastin, the protein that lets skin snap back. When elastin breaks down, fragments like this are released, and back in 1984 researchers showed VGVAPG attracts fibroblasts and monocytes in the lab, which is the basis for calling it a matrikine: a matrix fragment that tells repair cells to show up and get to work. The palmitoyl tail makes the peptide fat-friendly enough to cross the outer skin layer. A 2025 ex vivo study added a twist: on human skin samples the peptide reached the epidermis, used the skin's own calcium to form a gel, and helped dried-out, lipid-stripped skin hold water and stay less stiff. That reads more like a barrier and film effect than proof of new elastin being built.
Is Palmitoyl Hexapeptide-12 FDA approved?
No, Palmitoyl Hexapeptide-12 is not currently FDA approved. Current status: Cosmetic use - Widely available in skincare. Cosmetic ingredient, not an FDA-approved drug. No independent human efficacy trials published; the clinical claims come from small manufacturer studies.
Is Palmitoyl Hexapeptide-12 banned in sport?
Not named on the WADA Prohibited List (2026). As a topical cosmetic ingredient it is not a known anti-doping issue, but injecting it as an unapproved drug would fall under WADA's S0 catch-all.
What are the side effects of Palmitoyl Hexapeptide-12?
Reported side effects include: Generally well tolerated in cosmetic use, Mild redness or irritation (uncommon), Possible breakouts from the cream base in acne-prone skin, No meaningful systemic absorption expected from topical use. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Palmitoyl Hexapeptide-12?
Community-reported common dose: About 4% of the ingredient solution in a finished product (Once or twice daily). Range: Not standardized; depends on the supplier solution. Administration: Topical (serums, creams). Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Palmitoyl Hexapeptide-12 or used in similar applications.
GHK-Cu
Clinical TrialsGHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Skin & HairSnap-8
ResearchSNAP-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid topical cosmetic peptide, an extended cousin of Argireline that adds two residues to the same SNAP-25 mimic sequence. It is marketed as a needle-free way to soften expression lines, especially on the forehead and around the eyes. It is a cosmetic ingredient, not an approved drug, and the human evidence behind it is thin and mostly comes from the manufacturer.
Skin & HairArgireline
ResearchArgireline is the trade name for acetyl hexapeptide-8 (sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, also called acetyl hexapeptide-3), a synthetic peptide sold in anti-aging creams as a topical, needle-free alternative to Botox. It is designed to relax the muscle contractions behind expression lines. It is a cosmetic ingredient, not an FDA-approved drug, and the human efficacy data are genuinely mixed rather than settled.
Skin & HairMatrixyl
ResearchMatrixyl is the trade name (Sederma) for palmitoyl pentapeptide-4, also written Pal-KTTKS, a collagen-fragment peptide attached to a fatty acid so it can cross skin. Unlike Botox-mimic peptides, it does not touch muscle: it signals skin cells to rebuild collagen, so it is aimed at fine lines, firmness and skin texture rather than expression wrinkles. It is a cosmetic ingredient with one of the better-documented topical studies in the peptide space, though far short of drug-grade proof.
Skin & HairMatrixyl 3000
ResearchMatrixyl 3000 is Sederma's follow-up to the original Matrixyl, a fixed pair of two fatty-acid-tagged peptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The idea is a one-two punch: one peptide tells skin to rebuild collagen, the other calms the low-grade inflammation that wears collagen down. It is a cosmetic ingredient aimed at firmness, fine lines and aging skin, with supportive but mostly company-generated evidence.
Skin & HairCopper Peptide AHK-Cu
ResearchAHK-Cu is a synthetic copper-bound tripeptide, alanine-histidine-lysine complexed with a copper ion, engineered mainly for hair and scalp products. It is the lesser-known sibling of the naturally occurring GHK-Cu copper peptide, designed in the lab specifically to push hair follicles to keep growing. It is a cosmetic and research ingredient, not an approved hair-loss drug, and its evidence is essentially limited to one notable lab study.
Skin & HairWant updates on Palmitoyl Hexapeptide-12 research?
Get an email when we add new research here, when it is back in stock, or when the price drops.